Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Stock Now Rated “Hold” by Sell-Side Analysts

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) has been given an average rating of “Hold” by the five ratings firms that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three have assigned a buy recommendation to the company. The average 1 year price target among brokers that have covered the stock in the last year is $15.62.

ADIL has been the subject of a number of research analyst reports. Alliance Global Partners started coverage on shares of Adial Pharmaceuticals in a research report on Monday, August 3rd. They set a “buy” rating and a $11.00 target price for the company. Wall Street Zen raised shares of Adial Pharmaceuticals to a “sell” rating in a research report on Saturday, August 15th. Weiss Ratings upgraded shares of Adial Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday. Brookline Capital Markets downgraded shares of Adial Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, June 11th. Finally, Needham & Company LLC lowered shares of Adial Pharmaceuticals to a “buy” rating in a research report on Monday, June 15th.

Adial Pharmaceuticals Stock Performance

ADIL stock opened at $4.22 on Wednesday. The company has a market cap of $11.10 million, a PE ratio of -0.29 and a beta of 1.38. The stock has a 50-day moving average price of $4.73 and a two-hundred day moving average price of $3.01. Adial Pharmaceuticals has a 12-month low of $1.31 and a 12-month high of $10.75.

Adial Pharmaceuticals (NASDAQ:ADIL) last released its quarterly earnings data on Friday, August 14th. The company reported ($11.25) EPS for the quarter, missing analysts’ consensus estimates of ($1.03) by ($10.22).

Insiders Place Their Bets

In other Adial Pharmaceuticals news, major shareholder Coastlands Capital Lp purchased 10,053 shares of the firm’s stock in a transaction that occurred on Thursday, July 9th. The stock was purchased at an average cost of $2.79 per share, with a total value of $28,047.87. Following the transaction, the insider owned 383,375 shares in the company, valued at approximately $1,069,616.25. This trade represents a 2.69% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 8.00% of the company’s stock.

Adial Pharmaceuticals Company Profile

Adial Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for addiction and related disorders. The company’s primary focus is alcohol use disorder, a chronic condition characterized by problematic alcohol consumption and difficulty reducing or stopping use.

Adial’s lead investigational product, AD04, is an oral, genetically targeted therapy based on ondansetron, a selective serotonin-3 receptor antagonist. The company is studying AD04 as a potential treatment for alcohol use disorder in patients identified through genetic or biomarker-based testing.